Brought to you by 
EpiCept and Immune Pharmaceuticals merge
26 Aug 2013
Executive Summary
EpiCept Corp. (developing therapies for pain and cancer) will issue shares of its own common stock to acquire all of the outstanding shares of privately owned Immune Pharmaceuticals Ltd. (antibodies for inflammatory diseases and oncology). The value of the deal has not been disclosed, but is structured as a reverse merger, with EpiCept shareholders owning 22.5% of the combined entity--Immune Pharmaceuticals Inc.--and Immune Pharmaceuticals Ltd. shareholders owning 77.5%.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Stock
- Reverse Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
EpiCept and Immune Pharmaceuticals merge
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice